Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis

Among adults with pulmonary arterial hypertension who had received the diagnosis less than 1 year earlier, the addition of sotatercept to background therapy resulted in a lower risk of clinical worsening than placebo.